April 17, 2023
ÎçÒ¹¾ç³¡ School of Medicine
Sumitomo Pharma Co., Ltd.
i2medical LLC
A research group at ÎçÒ¹¾ç³¡, Sumitomo Pharma Co., Ltd. (Head Office: Osaka; Representative Director, President and CEO: Hiroshi Nomura), and i2medical LLC (Head of Development: Kuo-ching Liang) announced today that the Support Program for Screening of Depression / Rating of Severity, or "SWIFT" (tentative name, hereinafter "this product"), has been granted priority review by the Ministry of Health, Labour and Welfare (MHLW) as Japan's first Software as a Medical Device (SaMD). The group was led by ÎçÒ¹¾ç³¡ School of Medicine Project Professor Taishiro Kishimoto at the Hills Joint Research Laboratory for Future Preventive Medicine and Wellness together with Sumitomo Pharma Co., Ltd., and i2medical LLC, who have been developing this product for practical use.
For further information, please refer to the following PDF file.